TB-500

Thymosin beta-4's actin-grabbing mechanism is well mapped in the lab. Whether an injected synthetic version actually speeds tendon repair in a human body is a question the published research has never actually asked.

PCAC decided something about BPC-157 in July 2026, and most of the peptide world still can't say what, or what it doesn't mean.

TB-500's reputation rides on real experiments with thymosin beta-4 in animals. Whether that evidence covers the molecule people are actually injecting is a separate, open question.

TB-500 gets sold as an anti-inflammatory peptide. The animal studies behind that claim used a different molecule than the one in most vials, and nobody has tested whether timing during the wound's inflammatory window changes the outcome.

TB-500's reputation rests on tendon anecdote, but the peer-reviewed record on thymosin beta-4 is overwhelmingly cardiac: actin sequestration, epicardial progenitor signaling, coronary angiogenesis. No human cardiac trial exists, and grey-market TB-500 may not match the molecule studied.

PCAC voted to recommend BPC-157 and TB-500 for the FDA's 503A compounding list, each on its own 8-6 vote. Here's what the human trial record for each peptide shows, and where the case for stacking them turns from evidence into theory.

BPC-157, TB-500, and GHK-Cu are sold as one interchangeable injury-recovery stack, but their human evidence ranges from a real Phase 2 trial to a molecular identity gap to a null placebo-controlled result. Each is graded on its own record, not the group's pitch.

The Wolverine Stack pairs BPC-157 and TB-500 into one repair protocol — on paper a genuinely good idea: two peptides doing two different repair jobs. Here's what the pairing is meant to do for you, why the biology is exciting, and the one thing nobody has ever tested — the two of them run together.

Everyone heard "peptides are coming back." Almost nobody heard that the FDA already sat down with some of the most-stacked ones and voted no. Here's which, when, and what a July 2026 yes would actually buy you.

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

Two days at FDA's White Oak campus decided which of seven peptides US compounding pharmacies may eventually dispense by prescription. The recommendation is not an approval, the docket is not all the peptides, and the framing the forums used going in was mostly wrong.

Collagen is the scaffolding under your skin, tendons, and joints — and three peptides now in front of the FDA each lean on how your body builds it. Here is what that could mean for repair and ageing, why the biology is genuinely exciting, and how far the human proof actually goes.

Repair runs on fresh plumbing — new blood vessels growing into damaged tissue. It's the mechanism three of the most-talked-about recovery peptides — BPC-157, TB-500 and GHK-Cu — are built on. Here's what that could mean for how you heal, and the one question the same biology always raises.

BPC-157 and TB-500 aren't two flavours of one recovery peptide — they're unrelated proteins aimed at different kinds of damage. Here is what each could actually do for you, which one fits which injury, and how far the human proof goes for both.